KR101807704B1 - Method for generating induced pluripotent stem cells using reprogramming-enhancing agents - Google Patents
Method for generating induced pluripotent stem cells using reprogramming-enhancing agents Download PDFInfo
- Publication number
- KR101807704B1 KR101807704B1 KR1020110033789A KR20110033789A KR101807704B1 KR 101807704 B1 KR101807704 B1 KR 101807704B1 KR 1020110033789 A KR1020110033789 A KR 1020110033789A KR 20110033789 A KR20110033789 A KR 20110033789A KR 101807704 B1 KR101807704 B1 KR 101807704B1
- Authority
- KR
- South Korea
- Prior art keywords
- medium
- methyl
- culture
- cells
- differentiation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 17
- 210000004263 induced pluripotent stem cell Anatomy 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 61
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 29
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims abstract description 19
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims abstract description 19
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 15
- 238000012258 culturing Methods 0.000 claims abstract description 14
- 239000000411 inducer Substances 0.000 claims abstract description 9
- 239000002609 medium Substances 0.000 claims description 52
- 230000037361 pathway Effects 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 11
- 230000002188 osteogenic effect Effects 0.000 claims description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 9
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- -1 2-piperidin- 1 -ylethoxy Chemical group 0.000 claims description 5
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims description 5
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 4
- PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- JHSXDAWGLCZYSM-UHFFFAOYSA-N 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide Chemical compound CC1=CC(Cl)=CC=C1OCCCC(=O)NO JHSXDAWGLCZYSM-UHFFFAOYSA-N 0.000 claims description 3
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 claims description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical group ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 3
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims description 2
- JHDKZFFAIZKUCU-UHFFFAOYSA-N 3-[2-butyl-1-[2-(diethylamino)ethyl]benzimidazol-5-yl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)C=CC1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-UHFFFAOYSA-N 0.000 claims description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 2
- 102000045246 noggin Human genes 0.000 claims description 2
- 108700007229 noggin Proteins 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 2
- 229960000604 valproic acid Drugs 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 108010004165 polystatin Proteins 0.000 claims 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 210000001778 pluripotent stem cell Anatomy 0.000 abstract description 19
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 abstract description 16
- 229940123924 Protein kinase C inhibitor Drugs 0.000 abstract description 16
- 239000003881 protein kinase C inhibitor Substances 0.000 abstract description 16
- 238000004519 manufacturing process Methods 0.000 abstract description 13
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 8
- 230000008672 reprogramming Effects 0.000 description 7
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 6
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 6
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 6
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 6
- 229940112869 bone morphogenetic protein Drugs 0.000 description 6
- 230000032459 dedifferentiation Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 4
- 101150086694 SLC22A3 gene Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000008098 formaldehyde solution Substances 0.000 description 3
- 101150111214 lin-28 gene Proteins 0.000 description 3
- 229960005184 panobinostat Drugs 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- OSJFVOAURBIGTC-IFGWQFMBSA-N (2S,3R,4R,6R)-4-hydroxy-3-methoxy-2-methyl-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](O)[C@@H](OC)[C@]4(C)O1 OSJFVOAURBIGTC-IFGWQFMBSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- ZCBUQCWBWNUWSU-SFHVURJKSA-N ruboxistaurin Chemical compound O=C1NC(=O)C2=C1C(C1=CC=CC=C11)=CN1CCO[C@H](CN(C)C)CCN1C3=CC=CC=C3C2=C1 ZCBUQCWBWNUWSU-SFHVURJKSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- OAVGBZOFDPFGPJ-UHFFFAOYSA-N sotrastaurin Chemical compound C1CN(C)CCN1C1=NC(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C(C=CC=C2)C2=N1 OAVGBZOFDPFGPJ-UHFFFAOYSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 1
- HNICUWMFWZBIFP-IRQZEAMPSA-N 13(S)-HODE Chemical compound CCCCC[C@H](O)\C=C\C=C/CCCCCCCC(O)=O HNICUWMFWZBIFP-IRQZEAMPSA-N 0.000 description 1
- HXQRGYNEDCHJPJ-UHFFFAOYSA-N 2,6-diamino-n-[(1-tridecanoylpiperidin-2-yl)methyl]hexanamide Chemical compound CCCCCCCCCCCCC(=O)N1CCCCC1CNC(=O)C(N)CCCCN HXQRGYNEDCHJPJ-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- QMGUOJYZJKLOLH-UHFFFAOYSA-N 3-[1-[3-(dimethylamino)propyl]indol-3-yl]-4-(1h-indol-3-yl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(CCCN(C)C)C=C1C1=C(C=2C3=CC=CC=C3NC=2)C(=O)NC1=O QMGUOJYZJKLOLH-UHFFFAOYSA-N 0.000 description 1
- KIWODJBCHRADND-UHFFFAOYSA-N 3-anilino-4-[1-[3-(1-imidazolyl)propyl]-3-indolyl]pyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2C3=CC=CC=C3N(CCCN3C=NC=C3)C=2)=C1NC1=CC=CC=C1 KIWODJBCHRADND-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- AZRRZGIBBLWSSQ-UHFFFAOYSA-N 4-ethyl-7-phenyl-3,5-diazabicyclo[2.2.2]octane-2,6-dione Chemical compound N1C(=O)C2C(=O)NC1(CC)CC2C1=CC=CC=C1 AZRRZGIBBLWSSQ-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 1
- QQDIFLSJMFDTCQ-UHFFFAOYSA-N MC1568 Chemical compound CN1C(C=CC(=O)NO)=CC=C1C=CC(=O)C1=CC=CC(F)=C1 QQDIFLSJMFDTCQ-UHFFFAOYSA-N 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- PAWIYAYFNXQGAP-UHFFFAOYSA-N N-hydroxy-2-[4-[[(1-methyl-3-indolyl)methylamino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide Chemical compound C12=CC=CC=C2N(C)C=C1CNCC(CC1)CCN1C1=NC=C(C(=O)NO)C=N1 PAWIYAYFNXQGAP-UHFFFAOYSA-N 0.000 description 1
- GGCVZBXZNNYSTP-UHFFFAOYSA-N N1C=C(C2=CC=CC=C12)C=1C(=O)NC(C1)=O.N1C=CC2=CC=CC=C12 Chemical compound N1C=C(C2=CC=CC=C12)C=1C(=O)NC(C1)=O.N1C=CC2=CC=CC=C12 GGCVZBXZNNYSTP-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 description 1
- 229950008805 abexinostat Drugs 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 102000006533 chordin Human genes 0.000 description 1
- 108010008846 chordin Proteins 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229950005259 dacinostat Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- QKSGNWJOQMSBEP-UHFFFAOYSA-N diethyl-[[6-[[4-(hydroxycarbamoyl)phenyl]carbamoyloxymethyl]naphthalen-2-yl]methyl]azanium;chloride Chemical compound [Cl-].C1=CC2=CC(C[NH+](CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 QKSGNWJOQMSBEP-UHFFFAOYSA-N 0.000 description 1
- OAZUOCJOEUNDEK-UHFFFAOYSA-L disodium;(5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound [Na+].[Na+].C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 OAZUOCJOEUNDEK-UHFFFAOYSA-L 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229950010415 givinostat Drugs 0.000 description 1
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229950007812 mocetinostat Drugs 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- KBVSHAWWGLGKAI-UHFFFAOYSA-N pyridin-3-ylmethyl carbamate Chemical compound NC(=O)OCC1=CC=CN=C1 KBVSHAWWGLGKAI-UHFFFAOYSA-N 0.000 description 1
- 229950010654 quisinostat Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229950000261 ruboxistaurin Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229950005814 sotrastaurin Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
Abstract
The present invention relates to a method for producing a recombinant human somatic cell, comprising the steps of: (a) culturing a human-derived somatic cell into which a gene encoding a dediffering inducer is introduced in the presence of at least one selected from the group consisting of a protein kinase C inhibitor, a histone deacetylase inhibitor, Culturing in a medium containing a differentiation-enhancing agent; And (b) separating embryonic stem cell-like colonies from the culture obtained from step (a). The present invention also provides a method for producing iPS cells. The production method of the present invention is capable of producing reprogrammed pluripotent stem cells at high efficiency and also capable of producing reprogrammed pluripotent stem cells under xenopathogen-free and feeder cell-free conditions Can be manufactured.
Description
More particularly, the present invention relates to a method for producing a pluripotent stem cell comprising a protein kinase C inhibitor, a histone deacetylase inhibitor, and / or an osteogenic protein pathway inhibitor bone morphogenetic protein (BMP) pathway blocker) as a reprogramming-enhancing agent to produce or prepare reprogrammed pluripotent stem cells at high efficiency. In addition, the manufacturing method according to the present invention includes a method for producing reprogramming pluripotent stem cells under conditions of xenopathogen-free and feeder cell-free.
Induced pluripotent stem cells (iPS cells) refer to pluripotency cells obtained by differentiation from differentiated cells (for example, somatic cells) and are capable of differentiating into various organ cells. Since iPS cells can be obtained by reprogramming the cells differentiated by the differentiation inducing factors, it is possible to generate patient immunocompetent universal cell lines without somatic cell transfer. Therefore, iPS cells can be derived from the patient's cells, so immunization rejection can be avoided when applied to clinical applications. In addition, iPS cells do not use oocytes or embryos, so there is no bioethical controversy or religious criticism.
Takahashi, K., and Yamanaka, S., et al., In August 2006, first reported the formation of iPS cells by degeneration using mouse cells (Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. cell 126, 663-676) one since, Takahashi, K., etc., and Yu, J. et target human cells reported the formation of iPS cells by the de-differentiation Induction of pluripotent stem cells from adult cells (Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. human fibroblasts by defined factors Cell 131 , 861-872 and Yu, J., Vodyanik, MA, Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, JL, Tian, S., Nie, J. , Jonsdottir, GA, Ruotti, V., Stewart, R. , et al. (2007) Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. Takahashi, K. et al. Have found that induction factors of Sox2, Oct3 / 4, and Klf4 are essential for obtaining iPS cells, and additionally, c-Myc plays a role in promoting the formation of iPS cells. In addition, Yu, J. et al. Found that the induction factor of Sox2, Oct3 / 4, and Nanog is essential for obtaining iPS cells, and the formation of iPS cells is increased in the presence of Lin28.
On the other hand, according to a conventional method of producing iPS cells by reprogramming, for example, according to Takahashi, K. et al (2007) Cell 131 , 861-872, 5 x 10 4 human dermal fibroblasts There is a problem of low efficiency in which only about 10 iPS cells are obtained. In addition, since it requires the use of xenopathogen such as fetal bovine serum and the use of animal-derived feeder cells in the process of inducing the differentiation, There are limits to safety in clinical application.
The present inventors have conducted various studies to develop a method for producing iPS cells with high efficiency. As a result, it has been found that a specific substance, that is, a proteine kinase C inhibitor, a histone deacetylase inhibitor, and / or an osteogenic protein pathway blocker has an activity of promoting the differentiation of somatic cells and can produce iPS cells with high efficiency Respectively. In addition, when the protein kinase C inhibitor, the histone deacetylase inhibitor, and / or the osteogenic protein pathway blocker are used, it is possible to obtain a reverse transcription reaction under xenopathogen-free and feeder cell- We have found that pluripotent stem cells can be produced.
Accordingly, it is an object of the present invention to provide a process for producing iPS cells using a protein kinase C inhibitor, a histone deacetylase inhibitor, and / or an osteogenic protein pathway inhibitor as a reprogramming-enhancing agent.
According to one aspect of the present invention, there is provided a method for producing a recombinant human somatic cell comprising: (a) culturing human-derived somatic cells into which a gene encoding a reprogramming inducing factor has been introduced from a group consisting of a protein kinase C inhibitor, a histone deacetylase inhibitor, In a medium containing at least one selected reprogramming-enhancing agent; And (b) separating embryonic stem cell-like colonies from the culture obtained from step (a).
In a preferred embodiment of the present invention, the de-differentiation-enhancing agent is a mixture of a histone deacetylase inhibitor and an osteogenic protein pathway blocker, and the concentration of the de-differentiation-enhancing agent is in the range of 0.001 to 1000 μM Lt; / RTI >
In one embodiment of the present invention, said culturing of step (a) comprises the steps of: (i) culturing a medium obtained by adding said de-differentiation-enhancing agent to the medium used for introduction of the gene encoding the dedifferentiation inducing factor (" and performing a first incubation for 3-6 days in, (ii) in the presence of a substrate protein (extracellular matrix protein) other cells, and performing a secondary culture for 1.5~3 days in the first medium, and ( iii) performing a tertiary culture for 15 to 30 days in a culture medium obtained by adding the de-differentiation-enhancing agent to a human embryonic stem cell culture medium ("second medium").
The medium used for introducing the gene encoding the dediffering inducer and / or the culture medium for human embryonic stem cell culture may be a non-xenogeneic infectious agent medium, and the culture of (i) to (iii) Can be preferably performed under feeder cell-free conditions.
INDUSTRIAL APPLICABILITY According to the present invention, a method for producing stem cells capable of producing differentiated pluripotent stem cells can be carried out by using a protein kinase C inhibitor, a histone deacetylase inhibitor, and / or an osteogenic protein pathway blocker as a reprogramming- Can be manufactured. In addition, when the de-differentiation enhancer is used, the entire process for producing the dedifferentiated pluripotent stem cells can be performed under xenopathogen-free and feeder cell-free conditions. Thus, the method of the present invention can produce highly reprogrammed pluripotent pluripotent stem cells suitable for clinical use, that is, excellent safety.
Fig. 1 shows the results obtained when a medium treated with a combination of a protein kinase C inhibitor (Go6983, Go), a histone deacetylase inhibitor (tricostatin A, TSA) and an osteogenic protein pathway blocker (dorsomorphin, DM) , And the production efficiency (number of iPS cell colonies obtained per 10,000 cells) of the resulting human de-differentiating pluripotent stem cells.
FIG. 2 shows a medium treated with a combination of a protein kinase C inhibitor (Go6983, Go) and a histone deacetylase inhibitor (trichostatin A, TSA); Or Goetene kinase inhibitor (Go6983, Go) was used as a culture medium, the resultant immunodefined human pluripotent stem cells were immunostained using Tra1-60 antibody, which is an undifferentiated marker.
Figure 3 shows a medium treated with a combination of a protein kinase C inhibitor (Go6983, Go) and a histone deacetylase inhibitor (trichostatin A, TSA); Oct4, SSEA4, Tra1-60, and Sox2 when the medium treated with the protein kinase C inhibitor or the protein kinase C inhibitor (Go6983, Go) was used.
In the present specification, the term " induced pluripotent stem cells (iPS cells) ", also referred to as "reprogrammed pluripotent stem cells ", reprograms (i.e., quot; pluripotency "). The STEMs can be variously differentiated into long-term cells such as the brain and heart.
The present invention relates to a method for producing a recombinant human somatic cell, comprising the steps of: (a) culturing a human-derived somatic cell into which a gene encoding a dediffering inducer is introduced in the presence of at least one selected from the group consisting of a protein kinase C inhibitor, a histone deacetylase inhibitor, Culturing in a medium containing a differentiation-enhancing agent; And (b) separating embryonic stem cell-like colonies from the culture obtained from step (a).
The de-differentiation inducing factor includes all factors having a function to induce reprogramming, and preferably includes a combination of de-differentiation inducing factors known to be involved in reprogramming. For example, the dedifferentiation factor may be selected from the group consisting of Sox2, Oct3 / 4, Nanog, Klf4, Lin28, and Myc, which are known to induce reprogramming. The amino acid sequences and base sequences of Sox2, Oct3 / 4, Nanog, Klf4, Lin28, and c-Myc are known in GenBank and the like.
Derived somatic cells into which the gene encoding the dedifferentiation inducing factor is introduced can be obtained by a known method such as the method of Takahashi, K. et al. (Takahashi, K., et al., (2007) Cell 131 , 861- 872) and / or Yu, J. et al. (Yu, J., et al., (2007) Science, New York, NY). That is, somatic cells isolated from a human body are inoculated into a medium (for example, DMEM medium) containing fetal bovine serum and antibiotic substance (penicillin / streptomycin) Can be transferred to the human-derived somatic cells. The transfer of the gene encoding the dedifferentiation inducer can be carried out by culturing for one day, but is not limited thereto. On the other hand, the gene encoding the dedifferentiation inducer is transferred using a xenopathogen-free medium without xenopathogen such as fetal bovine serum, It is preferable in terms of clinical applicability of pluripotent stem cells. Therefore, it is preferable to use a xenopathogen-free medium such as MesenGro ™ hMSC Medium (StemRD, USA) for the introduction of the gene encoding the de-differentiation inducer. Can be used.
In the method of the present invention, the protein kinase C inhibitor includes all substances having a protein kinase C inhibitory activity. The protein kinase C inhibitor is selected from the group consisting of 3- [1- [3- (dimethylamino) propyl] -5-methoxy-1H-indol-3-yl] -4- (1H- (1H-indol-3-yl) -1H-pyrrole-2-
The histone deacetylase inhibitor may be N-hydroxy-3- (3-phenylsulfamoylphenyl) acrylamide, Belinostat, PXD101, PX105684 ); 7- (4- (3-ethynylphenylamino) -7-methoxyquinazolin-6-yloxy) -N-hydroxyheptanamide -yloxy) -N-hydroxyheptanamide, < / RTI >CUDC-101); [R- (E, E)] - 7- [4- (dimethylamino) phenyl] -N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide , E)] - 7- [4- (dimethylamino) phenyl] -N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide, Trichostatin A, TSA); N-hydroxy-N'-phenyloctanediamide (Vorinostat, SAHA, Zolinza, MK-0683); Valproic acid or its salt; Sodium butyrate; Benzo [d] imidazol-5-yl) -N-hydroxyacrylamide (3- (2-butyl-1- (2- (diethylamino) ethyl) -1H-benzo [d] imidazol-5-yl) -N-hydroxyacrylamide, SB939); N-hydroxy-N'-3-pyridinyloctanediamide (Pyroxamide, NSC 696085); 3- (dimethylaminomethyl) -N- [2- [4- (hydroxycarbamoyl) phenoxy] ethyl] -1-benzofuran-2-carboxamide [4- (hydroxycarbamoyl) phenoxy] ethyl] -1-benzofuran-2-carboxamide, PCI-24781, CRA-02478); N - [[4 - [[(2-aminophenyl) amino] carbonyl] phenyl] methyl] carbamic acid 3-pyridinyl methyl ester phenyl] methyl] carbamic acid 3-pyridinylmethyl ester, Entinostat, MS-275, SNDX-275, MS-27-275); (2-aminophenyl) -4 - [[(4-methylpiperazin-1-yl) pyridin-3-ylpyrimidin-2-yl) amino] methyl] benzamide, Mocetinostat, MGCDO103); 1-methyl-1H-pyrrol-2-yl] -N-hydroxy-2-propenamide (3- [5- (3- (3-Fluorophenyl) -3-oxopropen-1-yl) -1-methyl-1H-pyrrol-2-yl] -N-hydroxy-2-propenamide, MC1568; (N-hydroxy-3- [4 (4-fluorophenyl) ethyl] (E) -propenamide, Panobinostat, LBH-589, NVP-LBH589, LBH589); Phenyl] -2 (E) -propenhydrooxamic acid (3 < RTI ID = 0.0 > (E) -propenohydroxamic acid, Dacinostat, LAQ824, NVP-LAQ824) was prepared by the method described in Example 1, ; Methyl) piperazin-1 -yl) pyrimidine-5-carboxamide (prepared from N -hydroxy-2- (4 - (((1-methyl-1H-indol-3-yl) methyl) amino) methyl) piperidin-1-yl) pyrimidine-5-carboxamide, JNJ-26481585); [(6 - [(diethylamino) methyl] naphthalen-2-yl} methyl [4- (hydroxycarbamoyl) phenyl] carbamate [4- (hydroxycarbamoyl) phenyl] carbamate, Givinostat, Gavinostat, ITF2357, ITF 2357); And 4- (4-chloro-2-methylphenoxy) -N-hydroxybutanamide, Droxinostat). But is not limited to.
Also, the bone morphogenetic protein (BMP) pathway blocker may be noggin; Chordin; Follistatin; A) pyrimidine (6- (4- (2-tert-butoxycarbonylamino) phenyl) piperidin-1-ylethoxy) phenyl) -3-pyridin-4-ylpyrazolo (1,5-a) pyrimidine and dorsomorphin.
In the method of the present invention for producing dedifferentiated pluripotent stem cells, the de-differentiation-enhancing agent may be selected from the group consisting of a protein kinase C inhibitor, a histone deacetylase inhibitor, and an osteogenic protein pathway inhibitor, Especially preferably, a combination of a histone deacetylase inhibitor and an osteogenic protein pathway inhibitor can be used to produce a degenerated pluripotent stem cell with high efficiency.
The amount of the de-differentiation-enhancing agent, that is, the concentration in the medium may preferably be in the range of 0.001 to 1000 μM, more preferably 0.01 to 10 μM. Of course, the concentration range may be used if necessary.
The culture in the presence of the de-differentiation-enhancing agent, i.e. the culture of step (a)
(i) de-differentiation inducing the de-differentiation on the medium used for the introduction of a gene encoding a factor-enhancing agents added to the resulting medium (the "first medium") in a step of performing a first incubation for 3-6 days, (ii (Ii) carrying out a secondary culture in the first medium for 1.5 to 3 days in the presence of an extracellular matrix protein, and (iii) culturing the transformant in a medium for human embryonic stem cell culture, Followed by carrying out a third culture for 15 to 30 days in a medium obtained by adding the medium ("second medium").
In said step (i), said primary culture can be carried out for 3 to 6 days, for example for about 4 days. The medium used for the introduction of the gene encoding the dedifferentiation inducing factor is preferably a xenopathogen-free medium, for example, MesenGro ™ hMSC Medium (StemRD, USA) have.
The step (ii) is carried out in the presence of extracellular protein using the same medium as that used in step (i), and serves to pre-adapt the cells to the subsequent tertiary culture. Examples of the extracellular matrix proteins include coating proteins commonly used in cell culture such as vitronectin, Matrigel (BD Biosciences, USA), CellStart (Invitrogen, USA), gelatin gelatin, etc. may be used without limitation. The secondary culture may be performed for 1.5-3 days, for example about 2 days.
In the step (iii), the tertiary culture may be performed for 15 to 30 days, for example, for about 18 to 20 days. The culture medium for culturing human embryonic stem cells may be a culture medium commonly used for culturing human embryonic stem cells, but it is preferable to use a xenopathogen-free medium. For example, F-12 medium containing a genotype-free serum replacement, glutamax, non-essential amino acid, beta-mercaptoethanol, antibiotic, and basic fibroblast growth factor (bfgf). The basal medium may be a conventional cell culture medium as well as DMEM / F-12 medium such as DMEM (Dulbecco's Modified Eagle's Medium, GIBCO, USA); MEM (Minimal Essential Medium, GIBCO, USA); BME (Basal Medium Eagle, GIBCO, USA); RPMI 1640 (GIBCO, USA); DMEM / F-10 (Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-10; GIBCO, USA); α-MEM (α-Minimal Essential Medium; GIBCO, USA); G-MEM (Glasgow ' s Minimal Essential Medium, GIBCO, USA); IMDM (Isocove ' s Modified Dulbecco ' s Medium, GIBCO, USA); KnockOut DMEM (GIBCO, USA), and the like.
The cultivation of the above (i) to (iii) can be carried out particularly preferably without using animal-derived support cells, that is, under feeder cell-free conditions.
The production method of the present invention includes a step of separating embryonic stem cell-like colonies from the culture obtained from step (a) (i.e., step (b)).
Since the colonies of the pluripotent pluripotent stem cells have a morphologically distinct form in which the nuclei are relatively large and the cytoplasm is small and the round cells are clustered in the culture, They can be separated by physical methods using Pasteur pipettes.
Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrating the present invention, and the scope of the present invention is not limited to these examples.
Example 1.
The two 6-well plates MesenGro TM hMSC Medium (StemRD, USA) was added to (-A medium), human somatic cells the fat stromal cells (Adipose-derived stromal cell; ADSC ) (Lonza, USA) to a 1.5x10 5 cells per well (Takahashi, K. et al. (2007) Cell 131 , 861-872), and a gene encoding four kinds of dediffering inducers (Oct4 , Sox2, Klf4, c-Myc) (1 day incubation). As shown in the following Table 1, the depletion-enhancing agent was added to the medium-A to prepare the medium-A1 to the medium-A7, and the medium was changed to medium-A1 to medium-A7 every day for 4 days, Respectively.
Each well was treated with trypsin / EDTA and centrifuged, and the cells obtained from each well were inoculated into a 6 cm culture dish coated with vitronectin (5 / / ml, BD Biosciences, USA) to obtain about 5 × 10 4 cells Then, the cells were incubated for 2 days with the same daily medium (i.e. medium-A1 to medium-A7).
(GIBCO, USA), 1x glutamax (GIBCO, USA), 1% (v / v) nonessential amino acid (GIBCO, USA) Supplemented with 0.1 mM beta-mercaptoethanol (GIBCO), 1% (v / v) penicillin / streptomycin (GIBCO, USA) and 8 ng / ml bfgf (Chiba and Diostech, Korea) Cultured for 20 days while the culture medium of each well was changed daily with medium B1 to medium B7 (see Table 1) prepared by adding a differentiation-enhancing agent to DMEM / F-12 (GIBCO, USA) Respectively.
- Go: 3- [1- [3- (Dimethylamino) propyl] -5-methoxy-lH-indol-3-yl] -4- (lH- 5-dione) (Go6983)
- TSA: Trichostatin A (Trichostatin A)
- DM: dorsomorphin.
After the induction of differentiation induction factors, iPS cell colonies were observed to form in each well on the 20th day after the incubation, and hESC-like colonies were counted on the 25th day of culture. The results of measuring the number of iPS cell colonies obtained per 10,000 cells are shown in Fig. As can be seen from the results of FIG. 1, the number of iPS cell colonies in the group treated with the protein kinase C inhibitor, the histone deacetylase inhibitor, or the BMP pathway inhibitor increased by at least 2 times as compared with the control group. In particular, the number of iPS cell colonies in the group treated with both the histone deacetylase inhibitor (trichostatin A) and the BMP pathway inhibitor (dorsomorphin) was remarkably increased to 7 times or more as compared with the control group.
Test Example 1. Identification of iPS cells
In Example 1, iPS cell colonies in the culture medium of the fifth group (Go6983 + TSA) and the second group (Go6983) were stained using a Tra1-60 antibody (Millipore, USA) The expression of alkaline phosphatase, Oct4, SSEA4, Tra1-60, and Sox2, which are undifferentiated markers of iPS cell colonies, was measured.
That is, on the 25th day of culture, the colonies were washed with phosphate-buffered saline and fixed with 4% formaldehyde solution for 10 minutes. The cells were washed three times with phosphate-buffered saline for 10 minutes, and then blocked with 10% normal donkey serum at room temperature for 1 hour. The primary antibody, mouse Tra1-60 antibody (1: 500, Millipore, USA) was treated at room temperature for 1 hour, washed three times with phosphate-buffered saline for 10 minutes, and then incubated with a secondary antibody, biotinylated target anti-mouse IgG 1: 100, Vector Laboratory, USA) and incubated at room temperature for 30 minutes. After washing three times for 10 minutes with phosphate buffered saline, streptavidin-horseradish peroxydase conjugate (Vector Laboratory, USA) was treated at room temperature for 30 minutes, washed again with phosphate-buffered saline for 10 minutes three times, and then stained with DAB Peroxidase Substrate Kit Laboratory, USA).
In the same manner, the colonies were washed with phosphate-buffered saline, fixed with 4% formaldehyde solution for 10 minutes, and then subjected to alkaline phosphatase staining as follows. iPS cell colonies were washed three times for 10 minutes each and then washed with 100X NBT solution (50 mg / ml nitro blue tetrazolium (Sigma, USA) in a mixed solvent of 70% dimethylformamide and 30% water) and 100x XPHOS solution (100 mM Tris pH 8.5, 100 mM NaCl, 50 mM MgCl 2 ) was added to 10 mg / ml of 5-bromo-4-chloro-3-indolyl phosphate, disodium salt And iPS cell colonies were incubated for 30 minutes or more, followed by washing with H 2 O and observed.
In order to measure the expression of Oct4, SSEA4, Tra1-60, and Sox2, immunostaining was performed as follows. First, iPS cell colonies were washed with phosphate-buffered saline and fixed with 4% formaldehyde solution for 10 minutes. Mouse anti-Oct4 antibody (Santa Cruz, USA), mouse anti-SSEA4 antibody (Millipore, USA), mouse anti-Tra1-60 antibody (Millipore, USA) and mouse anti-Sox2 antibody (1: 200, Invitrogen, USA) for 1 hour at room temperature. The reaction mixture was washed three times with phosphate-buffered saline for 10 minutes at room temperature. The cells were washed three times with phosphate-buffered saline for 10 minutes, and stained with 30 nM 4 ', 6-diamidino-2-phenylindole (DAPI) (Invitrogen, USA). After washing three times with phosphate-buffered saline for 10 minutes, the cells were observed under a fluorescence microscope
The results obtained are shown in FIG. 2. The results are shown in FIG. 2. The results are shown in FIG. 2. The undifferentiated markers of the produced iPS cell colonies, alkaline phosphatase, Oct4, SSEA4, Tra1-60, and The results of measurement of Sox2 expression are shown in FIG. From the results of FIGS. 2 and 3, iPS cells produced according to the present invention showed positive responses to Tra1-60 antibody, and the undifferentiated markers of iPS cells, alkaline phosphatase, Oct4, SSEA4, Tra1-60 , And Sox2 were expressed well.
Claims (11)
(b) isolating embryonic stem cell-like colonies from the culture obtained from step (a)
Gt; (iPS) < / RTI > cells.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110033789A KR101807704B1 (en) | 2011-04-12 | 2011-04-12 | Method for generating induced pluripotent stem cells using reprogramming-enhancing agents |
| PCT/KR2012/002696 WO2012141471A2 (en) | 2011-04-12 | 2012-04-10 | Method for preparing induced pluripotent stem cells using a dedifferentiation enhancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020110033789A KR101807704B1 (en) | 2011-04-12 | 2011-04-12 | Method for generating induced pluripotent stem cells using reprogramming-enhancing agents |
Related Child Applications (20)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170137233A Division KR101807706B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells |
| KR1020170137246A Division KR101807720B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker |
| KR1020170137258A Division KR101810006B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells from human-derived somatic cells using reprogramming-enhancing agents |
| KR1020170137244A Division KR101807719B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker |
| KR1020170137254A Division KR101807728B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells from human-derived somatic cells |
| KR1020170137239A Division KR101807710B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells |
| KR1020170137311A Division KR101810012B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells from human-derived somatic cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker |
| KR1020170137249A Division KR101807722B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker |
| KR1020170137253A Division KR101807727B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells from human-derived somatic cells |
| KR1020170137236A Division KR101807708B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells |
| KR1020170137261A Division KR101810010B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells from human-derived somatic cells using reprogramming-enhancing agents |
| KR1020170137266A Division KR101810013B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells from human-derived somatic cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker |
| KR1020170137251A Division KR101807724B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells from human-derived somatic cells |
| KR1020170137379A Division KR101872782B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells using reprogramming-enhancing agents |
| KR1020170137270A Division KR101810014B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells from human-derived somatic cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker |
| KR1020170137242A Division KR101807713B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker |
| KR1020170137260A Division KR101810008B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells from human-derived somatic cells using reprogramming-enhancing agents |
| KR1020170137361A Division KR20170121122A (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells using reprogramming-enhancing agents |
| KR1020170137241A Division KR101807711B1 (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells |
| KR1020170137391A Division KR20170121124A (en) | 2017-10-23 | 2017-10-23 | Method for generating induced pluripotent stem cells using reprogramming-enhancing agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20120116193A KR20120116193A (en) | 2012-10-22 |
| KR101807704B1 true KR101807704B1 (en) | 2017-12-13 |
Family
ID=47009820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020110033789A KR101807704B1 (en) | 2011-04-12 | 2011-04-12 | Method for generating induced pluripotent stem cells using reprogramming-enhancing agents |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101807704B1 (en) |
| WO (1) | WO2012141471A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10131881B2 (en) | 2014-05-23 | 2018-11-20 | Bbhc | Method for preparing induced pluripotency stem cells from mesenchymal stem cells by using phlorotannin fraction |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101836523B1 (en) | 2012-10-18 | 2018-03-08 | 현대자동차주식회사 | Dct control method for vehicle |
| PT2970890T (en) * | 2013-03-14 | 2020-04-24 | Massachusetts Inst Technology | Compositions and methods for epithelial stem cell expansion and culture |
| WO2015178728A1 (en) * | 2014-05-23 | 2015-11-26 | 주식회사 비비에이치씨 | Method for preparing induced pluripotency stem cells from mesenchymal stem cells by using phlorotannin fraction |
| KR20230019500A (en) | 2014-09-03 | 2023-02-08 | 더 브리검 앤드 우먼즈 하스피털, 인크. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| KR102413235B1 (en) * | 2017-12-22 | 2022-06-24 | 고려대학교 산학협력단 | Placenta-derived cells conditioned media for inducing de-differentiation from somatic cell into induced pluripotent stem cell and method for inducing de-differentiation using the same |
| KR102051221B1 (en) * | 2018-07-24 | 2019-12-03 | 한국과학기술원 | Therapeutic composition capable of alleviating the inhibition of development of CFC syndrome patients |
| WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
| KR102131921B1 (en) * | 2018-10-30 | 2020-07-08 | 차의과학대학교 산학협력단 | Composition and kit for differentiating stem cells to neural progenitor cell, and method using the same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2367931B1 (en) * | 2008-12-03 | 2017-05-31 | International Stem Cell Corporation | Methods of deriving differentiated cells from stem cells |
-
2011
- 2011-04-12 KR KR1020110033789A patent/KR101807704B1/en active IP Right Grant
-
2012
- 2012-04-10 WO PCT/KR2012/002696 patent/WO2012141471A2/en active Application Filing
Non-Patent Citations (3)
| Title |
|---|
| Cell Stem Cell. 4(4):301-12 (2009.04.03.)* |
| Cell Stem Cell. 7(6):651-5 (2010.12.03.)* |
| Stem Cells. 29(4):618-28 (2011.04.05.)* |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10131881B2 (en) | 2014-05-23 | 2018-11-20 | Bbhc | Method for preparing induced pluripotency stem cells from mesenchymal stem cells by using phlorotannin fraction |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012141471A2 (en) | 2012-10-18 |
| WO2012141471A3 (en) | 2012-12-06 |
| KR20120116193A (en) | 2012-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101807704B1 (en) | Method for generating induced pluripotent stem cells using reprogramming-enhancing agents | |
| AU2016305705B2 (en) | Induced extended pluripotent stem cells, methods of making and using | |
| KR101313535B1 (en) | Culture media for maintaining stemness of human human embryonic stem cells or induced pluripotent stem cells and culture method using the same | |
| KR101807724B1 (en) | Method for generating induced pluripotent stem cells from human-derived somatic cells | |
| KR101807710B1 (en) | Method for generating induced pluripotent stem cells | |
| KR101810008B1 (en) | Method for generating induced pluripotent stem cells from human-derived somatic cells using reprogramming-enhancing agents | |
| KR101810010B1 (en) | Method for generating induced pluripotent stem cells from human-derived somatic cells using reprogramming-enhancing agents | |
| KR101810006B1 (en) | Method for generating induced pluripotent stem cells from human-derived somatic cells using reprogramming-enhancing agents | |
| KR101807728B1 (en) | Method for generating induced pluripotent stem cells from human-derived somatic cells | |
| KR101807727B1 (en) | Method for generating induced pluripotent stem cells from human-derived somatic cells | |
| KR101872782B1 (en) | Method for generating induced pluripotent stem cells using reprogramming-enhancing agents | |
| KR101807720B1 (en) | Method for generating induced pluripotent stem cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker | |
| KR101807722B1 (en) | Method for generating induced pluripotent stem cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker | |
| KR101807719B1 (en) | Method for generating induced pluripotent stem cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker | |
| KR101810013B1 (en) | Method for generating induced pluripotent stem cells from human-derived somatic cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker | |
| KR101807713B1 (en) | Method for generating induced pluripotent stem cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker | |
| KR101807706B1 (en) | Method for generating induced pluripotent stem cells | |
| KR101807708B1 (en) | Method for generating induced pluripotent stem cells | |
| KR101807711B1 (en) | Method for generating induced pluripotent stem cells | |
| KR101810012B1 (en) | Method for generating induced pluripotent stem cells from human-derived somatic cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker | |
| KR101810014B1 (en) | Method for generating induced pluripotent stem cells from human-derived somatic cells using histone deacetylase inhibitor and bone morphogenetic protein pathway blocker | |
| KR20170121124A (en) | Method for generating induced pluripotent stem cells using reprogramming-enhancing agents | |
| KR20170121122A (en) | Method for generating induced pluripotent stem cells using reprogramming-enhancing agents | |
| WO2021233116A1 (en) | Chemically-defined and xeno-free culture system for pluripotent stem cells | |
| KR20110085231A (en) | Components of stem cell culture media for either maintaining stemness or inducing differentiation of stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| A107 | Divisional application of patent | ||
| GRNT | Written decision to grant |